News
6d
MedPage Today on MSNSGLT2 Inhibitor Shows Promise as MASH TreatmentCurrently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...
Premenopausal women referred to a bone disease referral program at a tertiary medical center were evaluated for secondary versus idiopathic osteoporosis. [10] A retrospective review of all ...
aDepartment of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA bDivision of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA cDivision of ...
Results were similar after stratification by primary versus secondary prevention ICD. Relative to controls, ICD patients had more traffic contraventions in the 3 years prior to ICD implantation but ...
The primary outcome of this study was the cumulative incidence of EVB. Secondary outcomes were the cumulative incidences of other upper gastrointestinal bleeding (UGIB), first/further non-bleeding ...
The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience.
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug FBI Arrests Chinese Researchers For Attempting To Smuggle 'Potential Agroterrorism Weapon' — Kash ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results